mevidalen mevidalen mevidalen (developmental code name ly-3154207) is a dopaminergic drug which is under development for the treatment of lewy body disease, including those with parkinson's disease. it acts as a selective positive allosteric modulator (pam) of the dopamine d1 receptor. the drug is orally active and crosses the blood–brain barrier. it is a tetrahydroisoquinoline and is a close analogue of detq, another d1 receptor pam. mevidalen has been found to have wakefulness-promoting effects in sleep-deprived humans. side effects of mevidalen have been reported to include increased heart rate and blood pressure, insomnia, dizziness, nausea, vomiting, anxiety, nervousness, fatigue, headaches, palpitations, and contact dermatitis, as well as falls in those with dementia. as of march 2022, mevidalen is in phase 2 clinical trials for the treatment of lewy body disease. besides for movement disorders and dementia, d1 receptor pams like mevidalen might have value in the treatment of certain neuropsychiatric disorders, such as depression, excessive somnolence, and attention deficit hyperactivity disorder. mevidalenclinical dataother namesly-3154207; ly3154207identifiers iupac name 2-(2,6-dichlorophenyl)-1-ethanone cas number1638667-79-4pubchem cid86290953iuphar/bps10506chemspider58985571unii4a3702a96fkeggd11826chemblchembl3421729chemical and physical dataformulac24h29cl2no3molar mass450.40 g·mol−13d model (jsmol)interactive image smiles c1c2=cc=cc(=c2c(n1c(=o)cc3=c(c=cc=c3cl)cl)co)ccc(c)(c)o inchi inchi=1s/c24h29cl2no3/c1-15-18-7-4-6-16(10-11-24(2,3)30)19(18)12-17(14-28)27(15)23(29)13-20-21(25)8-5-9-22(20)26/h4-9,15,17,28,30h,10-14h2,1-3h3/t15-,17+/m0/s1key:xhcsbqbbgnqins-dotoqjqbsa-n